We are here to break the isolation so often felt by those with these rare diseases, and we would be delighted to welcome you into our 'family'.
The aim of our website is to direct you as quickly as possible to our support services and to information you can trust on multiple endocrine neoplasia (MEN) types 1, 2, and 3, medullary thyroid cancer (MTC), familial medullary thyroid cancer (FMTC), adrenal gland tumours (phaeochromocytomas), parathyroid hyperplasia, paragangliomas, familial isolated pituitary adenoma (FIPA) and succinate dehydrogenase (SDH) disorders.
Four research projects totaling £50,000 will be funded by AMEND this year.
Thanks to some exceptional fundraising by members and supporters during 2014, a special one-off fund of £40,000 was available specifically for research into medullary thyroid cancer (MTC), the most common cause of death in MEN2. MTC also occurs alone and independently of MEN. Winners this year were Professor Neil McDonald (London), Professor Chris McCabe (Birmingham) and Laura Moss (Cardiff).
As usual, the annual award of £10,000 was available for projects to do with MEN as a whole. This year's winner was Dr Paul Newey (Dundee).
AMEND is delighted to be able to fund such a range of valuable research opportunities this year.
AMEND CEO, Jo Grey, and brave volunteer, Lu launched a new awareness raising campaign today to encourage other patients to be proud of their scars.
'Scars are our story and are nothing to be embarrassed about' said Jo.
Jumping on the backlash advertising to the controversial dieting powder, Jo and Lu with the help of AMEND's graphic designer, produced their own images to help others feel more confident on the beach in summer.
'Your scars show that you have been through a battle and came out victorious!' comments Lu.